Cost ‐effectiveness of treating wet age‐related macular degeneration at the Kuopio University Hospital in Finland based on a two‐eye Markov transition model
ConclusionA two‐eye Markov transition model was developed to analyse the cost‐effectiveness of wet AMD treatment, as quality of life years (QALYs) are largely based on the visual acuity of the better‐seeing eye. Monthly injected bevacizumab was the most cost‐effective treatment and monthly ranibizumab the least effective.
Source: Acta Ophthalmologica - Category: Opthalmology Authors: Pasi Vottonen, Eila Kankaanp ää Tags: Original Article Source Type: research
More News: Avastin | Blindness | Health | Health Management | Lucentis | Opthalmology | Ranibizumab Injection | Study